Header graphic for print
The Healthcare Investor Insights on Issues & Trends that Impact Investments in Healthcare & Life Science Businesses

Baxter Delays PharMEDium Acquisition After Meningitis Outbreak

Posted in Healthcare Services Investing

Baxter International has placed its acquisition of PharMEDium Healthcare Corp. on hold following the nationwide meningitis outbreak, according to LBO Wire, a part of Dow Jones.

The outbreak has been tied by the Centers for Disease Control and Prevention and the Food and Drug Administration to New England Compounding Center.

While PharMEDium, which is backed by Oak Investment Partners and Baird Private Equity, has not been linked to any of the meningitis cases, the outbreak created enough uncertainty concerning the safety of compounding companies to delay Baxter’s planned acquisition, according to a Crain’s report.